Background: Lobular breast carcinoma usually shows poor responsiveness to chemotherapies and often lacks targeted therapies. Since FGFR1 expression has been shown to play pivotal roles in primary breast cancer tumorigenesis, we sought to analyze the status of FGFR1 gene in a metastatic setting of lobular breast carcinoma, since promising FGFR1 inhibitors has been recently developed. Methods: Fifteen tissue metastases from lobular breast carcinomas with matched primary infiltrative lobular breast carcinoma were recruited. Eleven cases showed loco-regional lymph-nodal and four haematogenous metastases. FGFR-1 gene (8p12) amplification was evaluated by chromogenic in situ hybridization (CISH) analysis. Her-2/neu and topoisomerase-IIα gene stat...
Fibroblast growth factors (FGFs) and their receptors (FGFRs) have been extensively investigated in s...
<div><p>Background and Aims</p><p>Amplification of the <i>fibroblast growth factor receptor 1</i> (<...
Clinical trials in patients with ER+ breast cancer with or without FGFR pathway somatic alterations ...
Lobular breast carcinoma usually shows poor responsiveness to chemotherapies and often lacks targete...
Purpose: Classic lobular carcinomas (CLC) account for 10% to 15% of all breast cancers. At the genet...
This is an open access article distributed under the terms of the Creative Commons Attribution Lice...
Introduction: Gene amplification is an important mechanism for activating oncogenes in malignant tum...
Amplification of the fibroblast growth factor receptor 1 (FGFR1) is believed to predict response to ...
Breast cancer, the main cancer in women, occurs in approximately 27% of all yearly diagnosed cancer ...
Invasive lobular carcinoma (ILC) is an understudied subtype of breast cancer that requires novel the...
The underlying mechanism of fibroblast growth factor receptor 1 (FGFR1) mediated carcinogenesis is s...
Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in similar to 10% of breast canc...
Purpose: While FGFR1 amplification has been described in breast cancer, the optimal treatment approa...
AbstractBACKGROUND:Endocrine resistance and metastatic dissemination comprise major clinical challen...
Introduction:Amplification of fibroblast growth factor receptor 1 (FGFR1) has been reported in squam...
Fibroblast growth factors (FGFs) and their receptors (FGFRs) have been extensively investigated in s...
<div><p>Background and Aims</p><p>Amplification of the <i>fibroblast growth factor receptor 1</i> (<...
Clinical trials in patients with ER+ breast cancer with or without FGFR pathway somatic alterations ...
Lobular breast carcinoma usually shows poor responsiveness to chemotherapies and often lacks targete...
Purpose: Classic lobular carcinomas (CLC) account for 10% to 15% of all breast cancers. At the genet...
This is an open access article distributed under the terms of the Creative Commons Attribution Lice...
Introduction: Gene amplification is an important mechanism for activating oncogenes in malignant tum...
Amplification of the fibroblast growth factor receptor 1 (FGFR1) is believed to predict response to ...
Breast cancer, the main cancer in women, occurs in approximately 27% of all yearly diagnosed cancer ...
Invasive lobular carcinoma (ILC) is an understudied subtype of breast cancer that requires novel the...
The underlying mechanism of fibroblast growth factor receptor 1 (FGFR1) mediated carcinogenesis is s...
Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in similar to 10% of breast canc...
Purpose: While FGFR1 amplification has been described in breast cancer, the optimal treatment approa...
AbstractBACKGROUND:Endocrine resistance and metastatic dissemination comprise major clinical challen...
Introduction:Amplification of fibroblast growth factor receptor 1 (FGFR1) has been reported in squam...
Fibroblast growth factors (FGFs) and their receptors (FGFRs) have been extensively investigated in s...
<div><p>Background and Aims</p><p>Amplification of the <i>fibroblast growth factor receptor 1</i> (<...
Clinical trials in patients with ER+ breast cancer with or without FGFR pathway somatic alterations ...